Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Neutral +5

Elevation Point Wealth Partners LLC Has $257,000 Stock Holdings in ...

AI-generated analysis

πŸ“‰ Elevation Point Wealth Partners LLC reduced its BDX holdings by 77.8% in Q1, selling 5,705 shares to retain only 1,632 shares valued at $257,000.

πŸ“ˆ Multiple institutional investors including Steph & Co., SHP Wealth Management, and Prosperity Bancshares Inc. added new stakes or significantly increased positions in Q4.

πŸ“Š Analyst consensus remains 'Hold' with a target price of $180.29, though Wells Fargo raised its objective to $161 while Stifel Nicolaus lowered it to $175.

πŸ’° The company recently paid a quarterly dividend of $1.05 per share, yielding 2.8% for investors of record on June 9th.

πŸ‘” CEO Thomas E. Polen, Jr. sold 2,764 shares worth $404,511 in early June under a pre-arranged Rule 10b5-1 trading plan.

πŸ“‰ EVP Michael David Garrison executed a sale of 1,100 shares for $160,226 on June 24th, reducing his position by 7.71%.

🏒 Total insider ownership stands at 0.40%, while institutional investors control 86.97% of the company's outstanding stock.

πŸ“ˆ BDX trades with a market cap of $41.93 billion and a P/E ratio of 38.52, currently priced between its 50-day and 200-day moving averages.

πŸ”¬ The medical technology giant manufactures single-use devices, infusion therapy solutions, and interventional technologies for healthcare institutions.

βš–οΈ Financial metrics show a debt-to-equity ratio of 0.62 and a dividend payout ratio of 106.33%, indicating the company is paying out slightly more than current earnings.

Bullish Signals
  • Several institutional investors, including Steph & Co., SHP Wealth Management, and Prosperity Bancshares Inc., initiated or significantly increased their stakes in Q4, signaling continued confidence from new capital.
  • Wells Fargo & Company raised its price objective to $161.00 and maintained an 'equal weight' rating, suggesting stability in the stock's valuation.
  • The company maintains a strong balance sheet with a debt-to-equity ratio of 0.62 and has declared a consistent quarterly dividend yielding 2.8%.
Risk Factors
  • Elevation Point Wealth Partners LLC drastically reduced its position by 77.8% in Q1, trimming holdings to a mere $257,000 after selling over 5,700 shares.
  • Stifel Nicolaus cut its price objective from $215.00 to $175.00 and maintained a neutral stance, reflecting concerns about current valuation levels.
  • Recent insider sales by CEO Thomas E. Polen, Jr. and EVP Michael David Garrison total over $564,000 in June, which can be interpreted as executives taking profits at current price levels.
  • The stock trades below its 200-day simple moving average of $167.81, indicating a longer-term downtrend or lack of bullish momentum relative to historical averages.
Full Analysis
Institutional ownership of Becton, Dickinson and Company (BDX) saw notable shifts in the first quarter, led by Elevation Point Wealth Partners LLC trimming its stake by 77.8% to just 1,632 shares worth $257,000 after selling over 5,700 shares. Conversely, several other firms including Steph & Co., SHP Wealth Management, and Prosperity Bancshares Inc. initiated or significantly increased their positions in the fourth quarter, collectively adding hundreds of thousands of dollars in value to their holdings. Analyst sentiment remains mixed with a consensus 'Hold' rating and a target price of $180.29, though individual targets vary widely from $157 to $215. Wells Fargo raised its objective to $161 with an 'equal weight' rating, while Stifel Nicolaus cut its target to $175. The stock trades at a P/E ratio of 38.52 and recently paid a quarterly dividend of $1.05 per share, resulting in a yield of 2.8%. Insider trading activity shows recent sales by top executives, including CEO Thomas E. Polen, Jr., who sold 2,764 shares for approximately $404,500 under a pre-arranged Rule 10b5-1 plan, and EVP Michael David Garrison, who sold 1,100 shares for roughly $160,000. These transactions represent small percentage decreases in their respective holdings but indicate continued liquidity among top management. BDX operates as a global medical technology company with a market capitalization of $41.93 billion, producing single-use devices, infusion therapy solutions, and interventional technologies. The company maintains a debt-to-equity ratio of 0.62 and trades above its 50-day moving average but below its 200-day average, reflecting a neutral-to-slightly-bearish technical stance amidst stable operational fundamentals.